Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant dabrafenib + trametinib for BRAF-mutated anaplastic thyroid cancer
NL-OMON51864Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in anaplastic thyroid cancer (ATC), sponsored by Amsterdam University Medical Center. Primary endpoint: R0 resection rate. Started Mar 2023; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NL-OMON51864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51864.